Dow Jones

38,686.32

1.51%

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

ROIV

Roivant Sciences (ROIV)

Roivant Sciences Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ROIV

1 2 3 4 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
30/05/2024	20:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
30/05/2024	15:46	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ROIV	Roivant Sciences Ltd
30/05/2024	06:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ROIV	Roivant Sciences Ltd
30/05/2024	06:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
16/05/2024	15:05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
02/04/2024	06:00	GlobeNewswire Inc.	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	NASDAQ:ROIV	Roivant Sciences Ltd
26/03/2024	17:22	PR Newswire (US)	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600	NASDAQ:ROIV	Roivant Sciences Ltd
13/02/2024	06:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
30/01/2024	15:05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
20/12/2023	15:30	GlobeNewswire Inc.	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	NASDAQ:ROIV	Roivant Sciences Ltd
14/12/2023	08:00	GlobeNewswire Inc.	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease	NASDAQ:ROIV	Roivant Sciences Ltd
28/11/2023	06:00	GlobeNewswire Inc.	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	NASDAQ:ROIV	Roivant Sciences Ltd
27/11/2023	07:00	GlobeNewswire Inc.	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus	NASDAQ:ROIV	Roivant Sciences Ltd
13/11/2023	06:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
10/11/2023	07:00	GlobeNewswire Inc.	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors	NASDAQ:ROIV	Roivant Sciences Ltd
30/10/2023	16:30	GlobeNewswire Inc.	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023	NASDAQ:ROIV	Roivant Sciences Ltd
23/10/2023	14:41	Dow Jones News	Trending: Roche to Buy Telavant From Roivant and Pfizer	NASDAQ:ROIV	Roivant Sciences Ltd
23/10/2023	06:18	IH Market News	Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more	NASDAQ:ROIV	Roivant Sciences Ltd
23/10/2023	03:16	Dow Jones News	Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update	NASDAQ:ROIV	Roivant Sciences Ltd
23/10/2023	00:50	Dow Jones News	Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal	NASDAQ:ROIV	Roivant Sciences Ltd
23/10/2023	00:00	GlobeNewswire Inc.	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant	NASDAQ:ROIV	Roivant Sciences Ltd
13/10/2023	07:00	GlobeNewswire Inc.	Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer	NASDAQ:ROIV	Roivant Sciences Ltd
26/09/2023	05:00	GlobeNewswire Inc.	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results	NASDAQ:ROIV	Roivant Sciences Ltd
11/09/2023	07:00	GlobeNewswire Inc.	Roivant Announces Completion of Redemption of its Outstanding Warrants	NASDAQ:ROIV	Roivant Sciences Ltd
17/08/2023	15:05	GlobeNewswire Inc.	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants	NASDAQ:ROIV	Roivant Sciences Ltd
14/08/2023	06:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
03/08/2023	15:05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023	NASDAQ:ROIV	Roivant Sciences Ltd
02/08/2023	15:05	GlobeNewswire Inc.	Roivant Announces Redemption of Outstanding Warrants	NASDAQ:ROIV	Roivant Sciences Ltd
27/07/2023	07:00	GlobeNewswire Inc.	Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease	NASDAQ:ROIV	Roivant Sciences Ltd
14/07/2023	06:51	IH Market News	Friday’s Wall Street Highlights: JPMorgan Chase, Coinbase, UPS, Theseus Pharmaceuticals, and more	NASDAQ:ROIV	Roivant Sciences Ltd